The global macular degeneration treatment market is poised for significant growth, projected to expand from USD 9.1 billion ...

In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in ...

Detailed price information for Adverum Biotechnologies Inc (ADVM-Q) from The Globe and Mail including charting and trades.

We recently compiled a list of the 10 Oversold Healthcare Stocks To Invest In. In this article, we are going to take a look ...

For people living with diabetes, vision complications require immediate attention. Diabetic macular edema (DME), a condition ...

Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery -- Multiple Events at Asia-Pacific ...

Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease ...

LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human ...

Age-Related Macular Degeneration market growth analysis. PORTLAND, OR, UNITED STATES, November 21, 2024 /EINPresswire / -- Increase in prevalence of age-re ...

Positive 3-year results from the phase III PHOTON study were presented at the recent American Academy of Ophthalmology (AAO) ...

Diabetic retinopathy (DR) is the primary cause of visual impairment among working-age populations in industrialized nations.

Detailed price information for Adverum Biotechnologies Inc (ADVM-Q) from The Globe and Mail including charting and trades.